Whan In Pharm Co.,Ltd. (016580.KS)
KRW 11930.0
(-0.33%)
KRW 11930.0
(-0.33%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 36.81 Billion KRW | -2.42% |
| 2022 | 34.67 Billion KRW | -0.69% |
| 2021 | 38.02 Billion KRW | 11.03% |
| 2020 | 32.48 Billion KRW | 5.71% |
| 2019 | 32.14 Billion KRW | 7.37% |
| 2018 | 31.98 Billion KRW | -9.38% |
| 2017 | 38.83 Billion KRW | 31.79% |
| 2016 | 23.81 Billion KRW | -9.83% |
| 2015 | 27.32 Billion KRW | 4.31% |
| 2014 | 25.89 Billion KRW | 20.59% |
| 2013 | 21.86 Billion KRW | 14.9% |
| 2012 | 19.76 Billion KRW | -19.27% |
| 2011 | 20.17 Billion KRW | 7.42% |
| 2010 | 22.77 Billion KRW | 10.97% |
| 2009 | 19.93 Billion KRW | 18.25% |
| 2008 | 18.49 Billion KRW | -2.47% |
| 2007 | 17.44 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 5.28 Billion KRW | -78.59% |
| 2024 Q2 | 8.92 Billion KRW | 143.39% |
| 2024 Q1 | 10.14 Billion KRW | 12.35% |
| 2023 FY | - KRW | -2.42% |
| 2023 Q1 | 10.16 Billion KRW | 21.95% |
| 2023 Q4 | 8.22 Billion KRW | -15.53% |
| 2023 Q3 | 9.73 Billion KRW | -15.39% |
| 2023 Q2 | 11.5 Billion KRW | 13.19% |
| 2022 Q2 | 8.8 Billion KRW | -22.82% |
| 2022 Q1 | 11.4 Billion KRW | 91.34% |
| 2022 Q4 | 8.33 Billion KRW | -9.16% |
| 2022 Q3 | 9.17 Billion KRW | 4.26% |
| 2022 FY | - KRW | -0.69% |
| 2021 Q3 | 8.92 Billion KRW | -5.67% |
| 2021 FY | - KRW | 11.03% |
| 2021 Q1 | 13.64 Billion KRW | 59.85% |
| 2021 Q2 | 9.46 Billion KRW | -30.64% |
| 2021 Q4 | 5.96 Billion KRW | -33.21% |
| 2020 Q3 | 9.83 Billion KRW | 37.12% |
| 2020 Q2 | 7.17 Billion KRW | -17.38% |
| 2020 FY | - KRW | 5.71% |
| 2020 Q1 | 8.67 Billion KRW | 49.1% |
| 2020 Q4 | 8.53 Billion KRW | -13.21% |
| 2019 Q4 | 5.82 Billion KRW | -26.6% |
| 2019 Q2 | 8.18 Billion KRW | -21.55% |
| 2019 Q1 | 10.43 Billion KRW | 71.87% |
| 2019 FY | - KRW | 7.37% |
| 2019 Q3 | 7.92 Billion KRW | -3.11% |
| 2018 Q1 | 7.3 Billion KRW | -2.64% |
| 2018 FY | - KRW | -9.38% |
| 2018 Q4 | 6.06 Billion KRW | -27.74% |
| 2018 Q3 | 8.39 Billion KRW | 0.37% |
| 2018 Q2 | 8.36 Billion KRW | 14.53% |
| 2017 Q4 | 7.5 Billion KRW | 1.52% |
| 2017 FY | - KRW | 31.79% |
| 2017 Q2 | 8.76 Billion KRW | -8.69% |
| 2017 Q1 | 9.6 Billion KRW | 80.84% |
| 2017 Q3 | 7.39 Billion KRW | -15.68% |
| 2016 Q4 | 5.3 Billion KRW | -24.08% |
| 2016 Q3 | 6.99 Billion KRW | 3.85% |
| 2016 Q2 | 6.73 Billion KRW | 8.51% |
| 2016 Q1 | 6.2 Billion KRW | -16.99% |
| 2016 FY | - KRW | -9.83% |
| 2015 Q4 | 7.47 Billion KRW | -14.02% |
| 2015 FY | - KRW | 4.31% |
| 2015 Q2 | 7.66 Billion KRW | 84.23% |
| 2015 Q3 | 8.69 Billion KRW | 13.46% |
| 2015 Q1 | 4.15 Billion KRW | -32.37% |
| 2014 Q3 | 7.95 Billion KRW | 20.45% |
| 2014 FY | - KRW | 20.59% |
| 2014 Q4 | 6.15 Billion KRW | -22.69% |
| 2014 Q2 | 6.6 Billion KRW | 7.84% |
| 2014 Q1 | 6.12 Billion KRW | -8.88% |
| 2013 Q2 | 5.37 Billion KRW | 13.25% |
| 2013 Q1 | 4.74 Billion KRW | 24.35% |
| 2013 FY | - KRW | 14.9% |
| 2013 Q4 | 6.72 Billion KRW | 24.06% |
| 2013 Q3 | 5.41 Billion KRW | 0.87% |
| 2012 Q1 | 4.06 Billion KRW | -27.71% |
| 2012 Q2 | 6.04 Billion KRW | 48.84% |
| 2012 Q3 | 5.42 Billion KRW | -10.23% |
| 2012 FY | - KRW | -19.27% |
| 2012 Q4 | 3.81 Billion KRW | -29.76% |
| 2011 FY | - KRW | 7.42% |
| 2011 Q2 | 7.95 Billion KRW | 42.73% |
| 2011 Q4 | 5.62 Billion KRW | 8.87% |
| 2011 Q1 | 5.57 Billion KRW | 17.67% |
| 2011 Q3 | 5.16 Billion KRW | -35.06% |
| 2010 Q2 | 6.13 Billion KRW | 23.06% |
| 2010 FY | - KRW | 10.97% |
| 2010 Q4 | 4.73 Billion KRW | -26.9% |
| 2010 Q3 | 6.47 Billion KRW | 5.51% |
| 2010 Q1 | 4.98 Billion KRW | 6.25% |
| 2009 Q1 | 4.9 Billion KRW | 86.08% |
| 2009 FY | - KRW | 18.25% |
| 2009 Q3 | 6.41 Billion KRW | 61.77% |
| 2009 Q2 | 3.96 Billion KRW | -19.2% |
| 2009 Q4 | 4.69 Billion KRW | -26.8% |
| 2008 FY | - KRW | -2.47% |
| 2008 Q1 | 6.12 Billion KRW | 56.84% |
| 2008 Q2 | 4.08 Billion KRW | -33.33% |
| 2008 Q3 | 3.96 Billion KRW | -2.79% |
| 2008 Q4 | 2.63 Billion KRW | -33.56% |
| 2007 Q4 | 3.9 Billion KRW | -20.42% |
| 2007 Q1 | 4.55 Billion KRW | 0.0% |
| 2007 Q2 | 4.5 Billion KRW | -1.2% |
| 2007 FY | - KRW | 0.0% |
| 2007 Q3 | 4.9 Billion KRW | 8.99% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -657.674% |
| Dong-A Socio Holdings Co., Ltd. | 141.36 Billion KRW | 73.961% |
| Ildong Holdings Co., Ltd. | -64.03 Billion KRW | 157.484% |
| HANDOK Inc. | 35.06 Billion KRW | -4.972% |
| Kukje Pharma Co., Ltd. | -1.03 Billion KRW | 3651.151% |
| Yuhan Corporation | 127.43 Billion KRW | 71.114% |
| Dong-A ST Co., Ltd. | 37.52 Billion KRW | 1.894% |
| SAMSUNG PHARM. Co., LTD. | -21.68 Billion KRW | 269.73% |
| Hanmi Pharm. Co., Ltd. | 323.33 Billion KRW | 88.615% |
| Hanall Biopharma Co.,Ltd | 4.99 Billion KRW | -637.635% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | -143.483% |
| Dong Sung Bio Pharm.Co.,Ltd. | 3.42 Billion KRW | -976.019% |
| MYUNGMOON Pharm co.,Ltd | 4.52 Billion KRW | -713.237% |
| Hana Pharm Co., Ltd. | 35.48 Billion KRW | -3.731% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -657.674% |
| Ilsung Pharmaceuticals Co., Ltd. | -18.47 Billion KRW | 299.278% |
| REYON Pharmaceutical Co., Ltd. | 6.55 Billion KRW | -461.565% |
| Aprogen pharmaceuticals,Inc. | -49.29 Billion KRW | 174.678% |
| JW Holdings Corporation | 187.88 Billion KRW | 80.408% |
| Ildong Pharmaceutical Co., Ltd. | -51.22 Billion KRW | 171.855% |
| Chong Kun Dang Pharmaceutical Corp. | 283.62 Billion KRW | 87.022% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 58.742% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 199.308% |
| Hyundai Pharmaceutical Co., Ltd. | 13.2 Billion KRW | -178.664% |
| Samil Pharmaceutical Co.,Ltd | 11.82 Billion KRW | -211.217% |
| Jeil Pharmaceutical Co.,Ltd | 18.65 Billion KRW | -97.323% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -657.674% |
| Kwang Dong Pharmaceutical Co., Ltd. | 54.97 Billion KRW | 33.039% |
| Daewoong pharmaceutical Co.,Ltd | 164.91 Billion KRW | 77.679% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 58.742% |
| Yuhan Corporation | 127.43 Billion KRW | 71.114% |
| Jeil Pharma Holdings Inc | 33.47 Billion KRW | -9.961% |
| Yungjin Pharm. Co., Ltd. | 7.64 Billion KRW | -381.192% |
| Suheung Co., Ltd. | 77.02 Billion KRW | 52.212% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 58.742% |
| Samjin Pharmaceuticals Co., Ltd. | 36.63 Billion KRW | -0.48% |
| Korea United Pharm Inc. | 70.78 Billion KRW | 47.994% |
| CKD Bio Corp. | -1.63 Billion KRW | 2357.689% |
| Daewon Pharmaceutical Co., Ltd. | 49.79 Billion KRW | 26.073% |
| Dongwha Pharm.Co.,Ltd | 32.56 Billion KRW | -13.049% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 199.308% |
| Chong Kun Dang Holdings Corp. | 62.28 Billion KRW | 40.899% |
| Boryung Corporation | 114.28 Billion KRW | 67.792% |
| Bukwang Pharmaceutical Co., Ltd. | -30.56 Billion KRW | 220.42% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | -143.483% |
| JW Lifescience Corporation | 50.82 Billion KRW | 27.58% |